Fintel reports that on October 30, 2025, Wells Fargo maintained coverage of Bio-Rad Laboratories (NYSE:BIO.B) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 21.85% Upside As of ...
The company doesn't seem like it will generate pops in key fundamentals anytime soon.
The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...
Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback